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Research Article
Fatty acid synthase mediates EGFR palmitoylation
in EGFR mutated non-small cell lung cancer
Azhar Ali1,*,† , Elena Levantini2,3,4,†, Jun Ting Teo1, Julian Goggi5, John G Clohessy3, Chan Shuo Wu1,
Leilei Chen1, Henry Yang1, Indira Krishnan3, Olivier Kocher3, Junyan Zhang3, Ross A Soo1,6,
Kishore Bhakoo5, Tan Min Chin1,7,‡,** & Daniel G Tenen1,2,‡,***
Abstract
Metabolic reprogramming is widely known as a hallmark of cancer
cells to allow adaptation of cells to sustain survival signals. In this
report, we describe a novel oncogenic signaling pathway exclu-
sively acting in mutated epidermal growth factor receptor (EGFR)
non-small cell lung cancer (NSCLC) with acquired tyrosine kinase
inhibitor (TKI) resistance. Mutated EGFR mediates TKI resistance
through regulation of the fatty acid synthase (FASN), which
produces 16-C saturated fatty acid palmitate. Our work shows that
the persistent signaling by mutated EGFR in TKI-resistant tumor
cells relies on EGFR palmitoylation and can be targeted by Orlistat,
an FDA-approved anti-obesity drug. Inhibition of FASN with Orlis-
tat induces EGFR ubiquitination and abrogates EGFR mutant
signaling, and reduces tumor growths both in culture systems and
in vivo. Together, our data provide compelling evidence on the
functional interrelationship between mutated EGFR and FASN and
that the fatty acid metabolism pathway is a candidate target for
acquired TKI-resistant EGFR mutant NSCLC patients.
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Introduction
Alterations in lipid metabolism are now gaining recognition as a
hallmark of cancer cells (Hirsch et al, 2010; Patterson et al, 2011;
Santos & Schulze, 2012). Metabolic pathway reprogramming in
cancer cells has been shown to support cancer cell proliferation and
survival (Cairns et al, 2011; Hanahan & Weinberg, 2011; Ward &
Thompson, 2012). The dependence of tumor cells on deregulated
lipid metabolism/biosynthesis indicates that proteins involved in
this process are attractive chemotherapeutic targets. In human cells,
lipid homeostasis is regulated via a feedback regulatory system by
sterol regulatory element-binding proteins (SREBPs) to balance and
maintain intracellular levels of fatty acid (FA) and cholesterol
(Horton et al, 2002). FASN is important in the synthesis of palmi-
tate, precursor of fatty acids, and is found frequently upregulated in
many human cancers (Menendez & Lupu, 2007; Ogino et al, 2008;
Migita et al, 2009). FASN is crucial for cancer cell survival, and its
overexpression has been associated with poor prognosis, higher risk
of cancer recurrence, and drug resistance, in colon and ovarian
cancer, breast and renal cell carcinomas (Alo’ et al, 1996; Gansler
et al, 1997; Horiguchi et al, 2008; Liu et al, 2008; Ogino et al,
2008). More importantly, enhanced FASN expression and activity
has been studied in lung squamous cell carcinomas and reported to
occur early in the development and progression of disease
(Piyathilake et al, 2000).
Despite significant progress in our understanding of the role of
lipid metabolism in cancers, there is still poor knowledge on the
mechanism/s involved. In addition, the relationship between the
roles of epidermal growth factor receptor (EGFR) and lipid signaling
remains unclear. With limited effective therapeutic options in non-
small cell lung cancer (NSCLC), identification of new targets for ther-
apeutic intervention is sorely needed. In this study, we investigated
the mechanisms of resistance to EGFR tyrosine kinase inhibitors
(TKIs) in NSCLC. Our data demonstrate a novel EGFR/FASN signal-
ing axis in acquired TKI-resistant NSCLC, which is abrogated by
forced EGFR silencing. Persistent EGFR signaling in TKI-resistant
EGFR mutated NSCLC cells is shown to be maintained through its
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palmitoylation. Palmitoylation of EGFR alters its cellular distribution
being frequently associated with its nuclear translocation. Further,
we observe that EGFR palmitoylation is important to support growth
of TKI-resistant EGFR mutated NSCLC cells. Pharmacological inhibi-
tion of FASN with Orlistat triggered cell death in TKI-resistant cells in
culture and reduced tumor burden in both xenografts and transgenic
mouse models. Altogether, these results demonstrate that the fatty
acid metabolic pathway is a candidate therapeutic target for the treat-
ment of tyrosine kinase inhibitor resistant EGFR mutant NSCLC.
Results
The fatty acid metabolic pathway is upregulated in EGFR mutant
NSCLC cells with acquired TKI resistance
To identify resistance-associated pathway signatures, microarray anal-
yses were carried out on parental PC-9 cells (termed PC-9P), which
harbor the clinically relevant EGFR delE746-A750 mutation rendering
them sensitive to the TKI drug Gefitinib, and resistant PC-9 cells are
referred to as PC-9GR. Prior microarray, DNA from PC-9GR was
analyzed and tested negative for EGFR T790M mutation and MET
amplification (Appendix Fig S1). After characterization of differen-
tially expressed genes, we utilized Gene Set Pathway Enrichment anal-
yses (GSEA) to identify enriched signaling pathways. Interestingly,
one of the enriched pathways associated with acquired Gefitinib resis-
tance was linked to fatty acid metabolic pathway. Appendix Table S1
lists the top 10 fatty acid metabolic pathway genes found to be upregu-
lated in PC-9GR when compared to PC-9P cells. These genes were
further validated by Q-PCR (Appendix Table S2). Of particular note,
FASN, a key regulatory gene for fatty acid synthesis, ranked first in
this list. Another highly upregulated gene was sterol regulatory
element-binding transcription factor 1 (SREBF1), encoding sterol regu-
latory element-binding protein 1 (SREBP1), which is the major tran-
scriptional regulator of FASN gene. To determine whether the fatty
acid pathway is important for TKI-resistant EGFR mutated NSCLC
growth, we evaluated the effect of Orlistat, a FASN inhibitor, on the
viability of Gefitinib-resistant EGFRdelL747-A749/A750P HCC4006GR
(negative for T790M and MET amplification; Appendix Fig S1), EGFR-
delE746-A750 H1650, and EGFRdelE746-A749/T790M H820 cells.
Viability assays showed that FASN inhibition through Orlistat
could effectively suppress growth of these TKI-resistant cells
(Appendix Fig S2). Together, these results suggest that the fatty acid
pathway is important, and its upregulation might contribute to
acquired TKI-resistant phenotype.
Acquired TKI-resistant in EGFR del746-750 NSCLC cell growth
shows elevated cellular free fatty acid and FASN expression,
which is suppressed by silencing EGFR
To investigate whether a link exists between constitutively active
EGFR signaling and growth of cells with Gefitinib resistance, both
PC-9P and PC-9GR cells were exposed to either Gefitinib or EGFR
siRNAs for 72 h. From hereon, the Gefitinib doses used for isogenic
PC-9 cells were 50 nM and 1 lM for both PC-9P and PC-9GR cells,
respectively. Gefitinib, at 50 nM, is selected as it represents the IC50
value of PC-9P while Gefitinib at 1 lM represents the highest clini-
cally achievable plasma level for the treatment of Gefitinib-resistant
cells (Cohen et al, 2004). Since PC-9GR cells were insensitive to
Gefitinib, EGFR siRNAs was utilized to inhibit EGFR expression, and
the efficacy of EGFR silencing was determined by Western blotting
(Appendix Fig S3A). Proliferation and viability assays demonstrated
that while Gefitinib failed to suppress growth of PC-9GR cells, EGFR
knockdown strongly decreased their survival and growth (Fig 1A
and B). To determine the specificity of EGFRi#1 siRNAs, we first
generated an EGFRi#1 resistant turboGFP (tGFP)-tagged EGFR cDNA
(EGFRdel386-391) through deleting 12 of 21 nucleotides of the EGFR
sequence targeted by EGFRi#1 siRNAs by site-directed mutagenesis
(Appendix Fig S3B). The specificity of EGFR knockdown by
EGFRi#1 was determined by transfecting tGFP-tagged EGFR or tGFP-
tagged EGFRdel386-391 into EGFRi#1-treated NL20 cells, followed
by measurement of EGFR mRNA using tGFP-specific primers. Quan-
titative PCR assays showed that tGFP-tagged EGFRdel386-391 was
resistant to EGFR knockdown by EGFRi#1 siRNAs, when compared
to tGFP-tagged EGFR (Appendix Fig S3C). Furthermore, cell cycle
analysis showed that both Gefitinib exposure and EGFR silencing
increased the apoptotic sub-G1 population in PC-9P cells while in
PC-9GR cells, sub-G1 was elevated only with EGFR silencing
(Appendix Fig S3D). We utilized a second EGFR siRNAs (EGFRi#2)
to demonstrate similar growth suppression in PC-9GR cells
(Appendix Fig S4A). Collectively, these results indicate that EGFR
signaling plays a role in the growth and survival of EGFR mutant
cells with acquired Gefitinib resistance that can no longer be
targeted by Gefitinib.
Given our microarray data demonstrating the upregulation of FA
metabolic genes in acquired TKI-resistant EGFR mutant NSCLCs, we
examined the relationship between EGFR signaling and fatty acid
synthesis. Therefore, cellular free fatty acids (FFAs) were measured
in both PC-9P and PC-9GR cells (Fig 1C). In PC-9P cells, cellular
FFAs remained unchanged with Gefitinib exposure, EGFR knock-
down, or combination of Gefitinib and EGFR knockdown (for 72 h),
when compared to vehicle-treated cells. FFAs level was about 45%
higher in PC-9GR, as compared to PC-9P cells. In PC-9GR cells, Gefi-
tinib exposure led to a significant elevation of cellular FFAs by
about 70%, as compared to vehicle (Fig 1C). Furthermore, EGFR
silencing of Gefitinib-treated PC-9GR cells, achieved by two inde-
pendent siRNAs (Fig 1C; Appendix Fig S4B), demonstrated reduced
cellular FFAs to levels similar to those of vehicle-treated cells. To
rule out that FFA elevation is not a consequence of Gefitinib off-
target effects, we utilized Erlotinib, a different EGFR-TKI, followed
by the analysis of cellular FFAs levels in Erlotinib-treated PC-9 cells.
Similar to that for Gefitinib, PC-9GR cells exhibited resistance to
Erlotinib when compared to PC-9P cells (Appendix Fig S5A). Similar
to Gefitinib, cellular FFAs were elevated in Erlotinib-treated PC-9GR
cells while FFAs levels were unaffected in Erlotinib-treated PC-9P,
when compared to vehicle-treated cells (Appendix Fig S5B). The
data suggest that upregulation of cellular FFAs in PC-9GR cells is an
EGFR-mediated pro-survival mechanism in response to EGFR-TKI
exposure.
To investigate the relationship between EGFR and fatty acid regu-
lation in cells with acquired Gefitinib resistance, we examined
SREBP1 and FASN protein expression in PC-9P and PC-9GR cells
exposed to Gefitinib for 48 and 72 h. In PC-9P cells, Gefitinib expo-
sure led to significant reduction of EGFR, SREBP1, and FASN
expression, after 72 h. However, in PC-9GR cells, EGFR expression
remained similar to vehicle after 48 and 72 h of Gefitinib exposure,
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while SREBP1 expression and FASN expression were both upregu-
lated at 48 h and remained elevated at 72 h (Fig 1D). Overall, these
data indicate that EGFR positively regulates SREBP1 and FASN
expression in acquired TKI-resistant EGFR mutated NSCLC.
Next, given that EGFR was causing upregulation of SREBP1 and
FASN, we also evaluated the effect of EGFR knockdown on SREBP1
and FASN expression in PC-9P and PC-9GR cells. EGFR silencing by
two different siRNAs was shown to strongly reduce SREBP1 and
FASN levels in both PC-9P and PC-9GR cells as compared to
untreated and scrambled-treated cells (Fig 1E; Appendix Fig S4C).
Moreover, we demonstrated that fatty acid synthesis could play a
crucial role in supporting the growth of acquired TKI-resistant EGFR
mutated HCC4006GR cells (Appendix Fig S6). We observed findings
similar to these in PC-9GR, in that the viability of Gefitinib-
untargetable HCC4006GR was suppressed by EGFR knockdown
(Appendix Fig S6A). Cellular FFAs were found higher by about 20%
in HCC4006GR, as compared to parental HCC4006P cells
(Appendix Fig S6B). Gefitinib exposure induced cellular FFAs eleva-
tion by about 40% in HCC4006GR, while FFAs levels remained the
same in HCC4006P cells, when compared to vehicle-treated cells
(Appendix Fig S6B). Silencing of EGFR in Gefitinib-treated
HCC4006GR cells led to reduced FFAs to levels similar to vehicle
(Appendix Fig S6B). Western blot analyses showed that SREBP1
and FASN protein expression upon Gefitinib treatment in
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Figure 1. Growth of TKI-resistant EGFR delE746-A750 PC-9 NSCLC cells is associated with elevated cellular free fatty acid and expression of FASN, and is
suppressed by EGFR knockdown.
Gefitinib doses used for these experiments were 50 nM for parental and 1 lM for Gefitinib-resistant PC-9 cells.
A,B Proliferation (n = 3, A) and viability (n = 3, B) assays on cells exposed to Gefitinib or EGFR siRNAs for 72 h. Significance in differences in proliferation and viability
indexes, in which vehicle acted as control, was determined by t-test. Error bars denote SEM.
C Measurement of cellular free fatty acid (FFA, n = 3) after Gefitinib treatment or EGFR knockdown for 72 h. Significance in differences in cellular FFA, normalized
against PC-9P vehicle, was determined by t-test. Error bars denote SEM.
D Western blot analysis of cells treated with either vehicle (72 h) or Gefitinib (48 and 72 h).
E Western blot analysis of cells exposed to either scrambled or EGFR siRNAs (EGFRi#1) for 72 h. ACTB was assessed as housekeeping gene. Vehicle cells acted as controls.
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HCC4006GR but not in HCC4006P cells (Appendix Fig S6C). Further,
HCC4006GR cells were resistant to Erlotinib in cell viability assays
(Appendix Fig S7A), and cellular FFAs were significantly elevated
with Erlotinib exposure, when compared to HCC4006P cells
(Appendix Fig S7B). The result showed that the induced FFAs seen
in HCC4006GR cells were a consequence of TKI resistance, therefore
eliminating any potential Gefitinib off-target effects. Collectively,
these results show that EGFR is involved in the regulation of fatty
acid synthesis via SREBP1/FASN and can be inhibited by ablation of
EGFR by siRNAs in EGFR mutant NSCLC cells with acquired TKI
resistance.
EGFR-FASN signaling is active in TKI-resistant EGFR T790M/L858R
NSCLC cells
In order to ascertain whether the EGFR-FASN regulatory network
was active in other Gefitinib-resistant NSCLC cells, carrying either
wild-type EGFR or different EGFR mutations, we examined H1975
(EGFR T790M/L858R) and H1703 (EGFR wild-type) cells
(Appendix Table S3). Proliferation and viability assays demonstrated
that while Gefitinib was weakly effective in Gefitinib-resistant H1975
and H1703 cells, EGFR silencing significantly reduced proliferation
and viability of H1975 but less so in H1703 cells (Fig 2A and B).
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Figure 2. The EGFR-FASN signaling network is active in TKI-resistant EGFR T790M/L858R NSCLC cells.
Gefitinib doses used for these experiments were 1 lM, and EGFR siRNAs (EGFRi#1) were at 25 nM.
A, B Proliferation (n = 3, A) and cell viability (n = 3, B) assays to determine the effects of Gefitinib or EGFR knockdown exposure on EGFR T790M/L858R H1975 and EGFR
wild-type H1703 cells after 72 h. Significance in differences in proliferation and viability indexes, in which vehicle acted as control, was determined by t-test. Error
bars denote SEM.
C Measurement of cellular free fatty acid (FFA, n = 3) after Gefitinib or EGFR knockdown for 72 h. Significance in differences in cellular FFA, in which vehicle acted as
control, was determined by t-test. Error bars denote SEM.
D Western blot analysis of H1975 and H1703 cells. Cells were treated with vehicle or Gefitinib for 72 h (left panel). Cells were exposed to either scrambled siRNA or
EGFR siRNAs for 72 h (right panel). Vehicle or scrambled-treated cells acted as controls. ACTB was selected as a housekeeping gene control.
Source data are available online for this figure.
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These results indicate that the Gefitinib-untargetable EGFR signaling
pathway is active in EGFR T790M/L858R NSCLC cells, and important
for the survival of EGFR mutated but less so for EGFR wild-type cells.
Therefore, we hypothesized that FFA-downstream pathways
might contribute to signals which are unresponsive to Gefitinib.
FFAs measurement in Gefitinib-resistant cells demonstrated that
Gefitinib exposure induced significantly higher cellular FFAs in
Gefitinib-resistant EGFR mutant H1975 cells, which could be abro-
gated by combined Gefitinib and EGFR knockdown when compared
to vehicle (Fig 2C). These molecular changes were not detected in
EGFR wild-type H1703 cells (Fig 2C). Additionally, Erlotinib was
weakly effective in both H1975 and H1703 cells (Appendix Fig S7C).
Moreover, Erlotinib induced cellular FFAs in H1975 cells but not in
H1703 cells, thus eliminating FFAs elevation to be a Gefitinib off-
target effect (Appendix Fig S7D). Overall, these data demonstrate
that the regulation of cellular FFAs by EGFR is restricted to
Gefitinib-resistant NSCLC cells carrying EGFR mutations.
Western blot analysis demonstrated the effects of EGFR gene
knockdown on SREBP1 and FASN protein expression. In Gefitinib-
treated H1975 cells, EGFR, as well as SREBP1 and FASN expression,
remained relatively unchanged compared to vehicle, whereas EGFR
knockdown resulted in significant loss of SREBP1 and FASN expres-
sion, as compared to scrambled-treated cells (Fig 2D upper panels).
In H1703 cells (carrying wild-type EGFR), Gefitinib exposure did not
affect EGFR, SREBP1, or FASN expression when compared to vehi-
cle, whereas EGFR knockdown led to an almost complete loss of
EGFR and SREBP1 expression, leaving FASN expression unaltered
when compared to scrambled-treated cells (Fig 2D lower panels).
To determine whether the unresponsiveness of SREBP1 and FASN
expression in H1703 cells is attributed to the lack of EGFR activity
due its wild-type status, we investigated the effects of EGFR hyper-
activation by EGF on SREBP1 and FASN expression in these cells.
Western blot data showed that SREBP1 and FASN expression
remained unaffected after EGFR activation, as demonstrated by the
induced EGFR phosphorylation at Y1068 (Appendix Fig S8). There-
fore, these results demonstrate that EGFR mutant proteins, not the
wild-type form, regulate SREBP1 and FASN expression in Gefitinib-
resistant H1975 NSCLC cells.
Akt signaling is active in acquired TKI-resistant EGFR mutated
NSCLC cells and is a critical EGFR downstream target pathway
The Akt pathway is known to be a major downstream effector of
EGFR signaling implicated in cell survival. To investigate whether
the pro-survival Akt signaling plays a role in acquired Gefitinib
resistance, we examined the effects of Gefitinib treatment and EGFR
knockdown in PC-9P and PC-9GR, as well as H1975 and H1703 cells
by Western blot analysis. Gefitinib treatment resulted in strong
reduction of EGFR, Akt, SREBP1, and FASN expression in PC-9P
cells (Appendix Fig S9A). However, EGFR, SREBP1, and FASN
expression remained relatively unaffected, as well as Akt activity, in
Gefitinib-resistant PC-9GR, H1975, and H1703 cells. Knockdown of
EGFR led to the abrogation of EGFR, SREBP1, and FASN expression,
as well as Akt activity, in PC-9P, PC-9GR, and H1975 cells. Akt path-
way activity remained intact in H1703 (wild-type) cells even after
Gefitinib exposure or EGFR knockdown. This result suggests that
pro-survival Akt is active in Gefitinib-resistant EGFR mutant NSCLC
cells and is abrogated by EGFR knockdown.
To validate the importance of Akt, we examined the effect of Akt
knockdown on the survival of NSCLC cells. The efficacy of Akt
knockdown in PC-9P, PC-9GR, H1975, and H1703 cells was deter-
mined by Western blot (Appendix Fig S9B). Results from viability
assays demonstrated that Akt silencing significantly reduced cell
viability (Appendix Fig S9C), indicating that Akt is important for the
growth of EGFR mutant and wild-type TKI-resistant NSCLC cells.
Overexpression of EGFR mutants prevents growth arrest in EGFR
knockdown NSCLC EGFR mutated cells with TKI resistance by
re-establishing FASN signaling
To determine whether EGFR mutation status was important in the
regulation of FASN for survival of TKI-resistant NSCLC cells,
isogenic PC-9 cells as well as H1975 and H1703 cells were selected,
as they possess distinct EGFR status and response to Gefitinib expo-
sure. These cells were treated with either EGFR siRNAs alone or in
combination with transfection of tGFP-tagged EGFR del746-750,
EGFR L858R/T790M, or EGFR wild-type vectors. Cellular prolifera-
tion assays showed that overexpression of EGFR mutant vectors
prevented growth arrest by EGFR knockdown in TKI-resistant EGFR
mutant PC-9GR and H1975 cells (Fig 3A), as compared to EGFR
wild-type H1703 cells, in which overexpression failed to prevent
EGFR knockdown-mediated growth arrest. Overexpression of EGFR
del746-750 in EGFR wild-type H1703 and EGFR wild-type in
EGFRdel746-750 PC-9P cells, however, did not increase cell growth
(Fig 3A). Similarly, cell viability assays showed increased viability
after EGFR mutant overexpression in TKI-resistant PC-9GR (EGFR
del746-750) and H1975 (EGFR L858R/T790M), but not in TKI-sensi-
tive PC-9P (EGFR del746-750) or TKI-resistant H1703 (EGFR wild-
type) cells (Appendix Fig S10). These results suggest that the EGFR-
mediated regulation on cell viability and proliferation, which we
have shown to be linked to FASN, is confined to NSCLC cells carry-
ing an EGFR mutation.
In order to confirm that the increased growth by EGFR mutant
overexpression in EGFR knockdown cells was indeed linked to
cellular FFAs levels, we performed cellular FFAs assays. EGFR
mutant overexpression significantly induced FFAs in EGFR knock-
down PC-9GR and H1975 cells (both carrying EGFR mutations),
whereas EGFR wild-type overexpression did not differ from the
scrambled control-treated cells in its ability to induce FFAs in these
cells (Fig 3B). Further, neither EGFR mutant nor wild-type overex-
pression affected FFAs in EGFR knockdown H1703 (EGFR wild-
type) or PC-9P (EGFR mutant) cells, as compared to scrambled
control. These results highlight a correlation between cellular FFAs
and EGFR-mediated FASN signaling in Gefitinib-resistant EGFR
mutated NSCLC cells.
The elevated growth rate observed after EGFR mutant overex-
pression correlated with SREBP1 and FASN expression in EGFR
knocked down EGFR mutants PC-9GR and H1975 cells. EGFR
mutant overexpression, however, was not able to increase FASN
expression in EGFR knockdown PC-9P cells. In EGFR wild-type
H1703 cells, FASN levels were similar to scrambled siRNAs after
EGFR wild-type overexpression (Fig 3C). These results demon-
strated that overexpression of EGFR mutant in EGFR silenced cells
correlated with SREBP1 and FASN re-expression in Gefitinib-
resistant EGFR mutated cells only. Together, the data suggest that
the increased cell growth imparted by EGFR mutant overexpression
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correlates with the re-establishment of EGFR-FASN signaling axis,
and this phenomenon is exclusive to Gefitinib-resistant EGFR
mutant NSCLC cells.
Palmitoylation of EGFR influences its cellular distribution and is
important for TKI-resistant EGFR mutant NSCLC cell growth
Palmitoylation is the covalent attachment of palmitate to cysteine
residues of protein (Linder & Deschenes, 2007; Blaskovic et al,
2013; Resh, 2016), which influences the localization, function, and
stability of modified proteins (Greaves & Chamberlain, 2007;
McCormick et al, 2008; Kong et al, 2013; Coleman et al, 2016). The
addition of saturated 16-carbon palmitate to EGFR has been previ-
ously reported (Macdonald-Obermann & Pike, 2009; Bollu et al,
2015; Runkle et al, 2016). Since we identified an EGFR-mediated
regulation of FASN in TKI-resistant EGFR mutant NSCLC cells, we
then asked whether EGFR is a target for palmitoylation. To deter-
mine this, we performed the in vitro acyl-biotin exchange (ABE)
assay to detect palmitoylation of EGFR in NSCLC cells. TKI-sensitive
cells (PC-9P), together with TKI-resistant (PC-9GR and H1975)
NSCLC and NL20 cells, immortalized non-transformed lung cells
carrying wild-type EGFR, were treated with Gefitinib to determine
whether response to TKIs was linked to EGFR palmitoylation. The
efficiency of EGFR immunoprecipitation for their respective cell
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Figure 3. EGFR mutant overexpression in EGFR knocked down TKI-resistant EGFR mutant NSCLC cells re-establishes FASN and prevents growth arrest.
A Proliferation assays (n = 3) of tGFP-tagged EGFR (wild type, DE746-A750, or L858R/T790M) overexpression in EGFR silenced cells. Cells were allowed to attach
overnight in 96-well format prior to transfection with EGFR siRNAs (EGFRi#1, 25 nM) for 12 h. This was followed by transfection with tGFP-tagged EGFR constructs
ranging from 0.1 to 0.5 lg in increments of 0.1 lg for additional 60 h (total 72 h). Significance in differences in proliferation index, in which EGFRi#1 cells acted as
controls, was determined by t-test. Error bars denote SEM.
B Cells were treated with either scrambled, EGFRi#1, EGFRi#1, and tGFP-tagged EGFR mutant combination, or EGFRi#1 and tGFP-tagged EGFR wild-type combinations
for 72 h. Cellular free fatty acid (n = 3) was then measured, and significance was determined by t-test with untreated cells as control. Error bars denote SEM.
C Western blot data showing EGFR, exogenous tGFP-tagged EGFR, SREBP1, and FASN expression in NSCLC cells, respectively. Cells were grown in 100-mm dishes
overnight prior to EGFR siRNAs (EGFRi#1) transfection for 12 h. This was followed by transfection of 6 lg of respective tGFP-tagged EGFR constructs with further
incubation of 60 h (total 72 h). ACTB was selected as housekeeping gene.
Source data are available online for this figure.
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lines was assessed before proceeding with the assay (Appendix Fig
S11). As shown in Fig 4A, Gefitinib exposure led to a strong upregu-
lation of EGFR palmitoylation in TKI-resistant PC-9GR, and weaker
induction in H1975 cells when compared to vehicle. In TKI-sensitive
cells, EGFR palmitoylation was greatly reduced by Gefitinib, while
EGFR palmitoylation was undetectable in NL20 control cells. These
findings indicate a tight correlation between EGFR palmitoylation
and TKI resistance in EGFR mutant cells.
Earlier, we have shown that the reversal of growth arrest after
EGFR mutant overexpression in EGFR knockdown TKI-resistant
EGFR mutants PC-9GR and H1975 cells was accompanied by EGFR
re-expression. We then asked whether the re-expressed EGFR was
palmitoylated, and we were able to observe that indeed re-expres-
sion of mutant EGFR correlated with palmitoylation in both PC9-GR
and H1975 NSCLC cells (Fig 4B). To ascertain whether mutated
EGFR is preferentially palmitoylated, we performed in vitro palmi-
toylation of tGFP-tagged EGFR under cell-free conditions. In vitro
translated tGFP-tagged wild-type, EGFR del746-750, and EGFR
L858R/T790M proteins were incubated with cellular extracts from
PC-9GR, H1975, and H1703 cells followed by ABE assay and
Western blot. In Fig 4C, Western blot images showed that IVT EGFR
del746-750 and L858R/T790M proteins were preferentially palmitoy-
lated when incubated in PC-9GR and H1975 lysates, while IVT EGFR
wild-type proteins remained unpalmitoylated. None of the IVT
tGFP-tagged EGFR proteins was palmitoylated after incubation with
H1703 lysates. Therefore, palmitoylation appears to be exclusively
confined to mutant EGFR suggesting that, in TKI-resistant NSCLC,
the structure of mutant EGFR and/or interaction with effector
protein/s may have influenced its palmitoylation.
We then asked whether EGFR palmitoylation influences its cellu-
lar distribution/localization in TKI-resistant NSCLC cells carrying
EGFR mutations. We performed nuclear, cytosolic, and membrane
fractionation to compare EGFR distribution between TKI-resistant
PC-9GR and H1975, as well as TKI-sensitive PC-9P cells. Cellular
fractionations were then subjected to co-immunoprecipitation of
EGFR followed by in vitro ABE assay to detect EGFR palmitoylation.
From Fig 4D, Western blot images showed that EGFR was predomi-
nantly localized in cytosolic and membrane fractions of both TKI-
resistant (PC-9GR and H1975) and sensitive (PC-9P) vehicle-treated
cells. However, we observed EGFR in the nuclear fractions of vehi-
cle-treated TKI-resistant PC-9GR and H1975 cells, which was not
evident in the TKI-sensitive PC-9P cells. Interestingly, Western blot
analysis of palmitoylated EGFR revealed that palmitoylated EGFR
could be detected only in the membrane fractions of TKI-sensitive
PC-9 cells. Palmitoylated EGFR was detected mainly in the nuclear
and cytosolic fractions of TKI-resistant PC-9GR and H1975 cells, and
much less so in the membrane fractions. Palmitoylation inhibition
resulted in disappearance of EGFR in the nuclear fractions of 2-
bromopalmitic acid (2-BP)-treated PC-9GR and H1975 cells (Fig 4D).
The data suggest that palmitoylation appears to influence EGFR
distribution. More specifically, there is a correlation between EGFR
palmitoylation and its nuclear translocation in TKI-resistant EGFR
mutated NSCLC cells. Next, to determine whether palmitoylation is
important for the survival of TKI-resistant EGFR mutated cells, we
carried out rescue assay with the supplementation of palmitate after
2-BP treatment in PC-9P, PC-9GR, H1975, and NL20 cells. Results
from cell viability assays showed that exogenous palmitate
improved the viability of 2-BP exposed PC-9GR and H1975, but not
PC-9P and NL20 cells (Fig 4E). This finding suggests that palmitoy-
lation is required specifically for the survival of TKI-resistant EGFR
mutated NSCLC cells.
Three cysteine residues—Cys797, Cys1049, and Cys1146, located
within the EGFR cytoplasmic tail were identified to be important
sites for its palmitoylation (Bollu et al, 2015; Runkle et al, 2016). To
investigate whether there is a functional role of EGFR palmitoyla-
tion, we created two separate palmitoylation-deficient tGFP-tagged
EGFR mutant constructs—carrying del746-750 and L858R/T90M,
respectively, in which cysteine residues 797, 1,049, and 1,146 were
mutated to alanine. The palmitoylation-deficient EGFR constructs
were then transfected into PC-9GR (del746-750) and H1975 (L858R/
T790M) cells, followed by co-immunoprecipitation of EGFR and
in vitro ABE assay. The loss of palmitoylation expressed by these
▸Figure 4. Palmitoylation of EGFR alters its cellular distribution and is crucial for growth of TKI-resistant EGFR mutated NSCLC cells.A Western blot analysis showing EGFR palmitoylation levels in PC-9P, PC-9GR, H1975, and NL20 cells treated with Gefitinib for 72 h. Hydroxylamine (HAM) is a strong
reducing agent that cleaves palmitate from cysteine residues and is necessary for biotinylation. The omission of HAM cleavage (HAM-) serves as negative control for
ABE assay.
B Western blot data showing EGFR palmitoylation in cells treated with either scrambled, EGFRi#1, EGFRi#1 plus tGFP-tagged EGFR mutant combination, or EGFRi#1
plus tGFP-tagged EGFR wild-type for 72 h. tGFP-tagged EGFR is about 197 kDa, while EGFR is 170 kDa.
C Western blot analysis showing palmitoylation of mutated EGFR under cell-free conditions. Cell-free synthesized tGFP-tagged EGFR was generated by in vitro
translation using vectors containing EGFR wild-type or mutants (del746-750 or L858R/T790M), with no DNA/template as negative control. Fresh extracts of PC-9GR,
H1975 and H1703 cells were prepared in hypotonic buffer. For in vitro palmitoylation, synthesized tGFP-tagged EGFR was incubated in cell extracts for 1 h at 37°C,
followed by ABE assay and Western blotting.
D Vehicle- and 2-bromopalmitic acid (50 lM of 2-BP)-treated cells were harvested and cellular fractionation was carried out to obtain nuclear, cytosolic, and
membrane fractions and a part of these fractions were analyzed by Western blotting to detect EGFR. The remaining fractions were subjected to EGFR pulldown by
anti-EGFR antibody and in vitro ABE assay. Palmitoylation of EGFR was then determined by Western blot analysis.
E Cell viability assays (n = 3) of cells were first treated with 250 lM of 2-BP for 24 h, followed by the supplementation of 10 lM of palmitate and a further incubation
for 48 h. Significance in differences in viability index, in which 2-BP-treated cells acted as controls, was determined by t-test. Error bars denote SEM.
F Growth curves (n = 3) illustrating the proliferation index of cells treated with scrambled, EGFR siRNAs (EGFRi#1) alone or in combination with transfection of tGFP-
tagged EGFR mutant (del746-750 or L858R/T790M) constructs with or without C797A/C1049A/C1146A mutations for 72 h. Significance in differences in proliferation
index, in which EGFRi#1 cells acted as controls, was determined by t-test. Error bars denote SEM.
G Cells were transfected with tGFP-tagged EGFR mutant (del746-750 or L858R/T790M) constructs with or without C797A/C1049A/C1146A mutations and harvested after
72 h. Cellular fractionation was performed to separate nuclear, cytosolic, and membrane fractions. Fractionates were then analyzed by Western blot analysis to
detect the distribution of tGFP-tagged EGFR with anti-tGFP antibody.
Source data are available online for this figure.
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palmitoylation-deficient tGFP-tagged EGFR mutant constructs was
first verified by Western blotting (Appendix Fig S12). Results from
cell proliferation assays showed that overexpression of palmitoyla-
tion-deficient EGFR mutants did not affect the growth decrease in
EGFR knocked down PC-9GR and H1975 cells, contrary to cells
carrying the solely EGFR mutant constructs (Fig 4F). These data
indicate that EGFR palmitoylation is important for the growth and
survival of TKI-resistant EGFR mutant PC-9GR and H1975 cells.
Next, we asked whether palmitoylation is necessary for the
nuclear translocation of EGFR in TKI-resistant EGFR mutant NSCLC
cells. To investigate this, we transfected PC-9GR (del746-750) and
H1975 (L858R/T790M) with relevant palmitoylation-deficient tGFP-
tagged EGFR mutant constructs, followed by nuclear, cytosolic, and
membrane fractionation, and the distribution of tGFP-tagged EGFR
mutants was detected by Western blot analysis. Western blot images
showed that high EGFR was present in the membrane fractions,
with lesser amounts detected in the nuclear and cytosolic fractions
of PC-9GR and H1975 cells (Fig 4G). In comparison with tGFP-
tagged EGFR, the distribution of palmitoylation-deficient tGFP-
tagged EGFR was found predominantly in the membrane fractions
of both cells with no changes to EGFR expression in cytosolic frac-
tions while nuclear EGFR was undetectable (Fig 4G). The results
suggest that those cysteine residues are important for the nuclear
translocation of EGFR in TKI-resistant EGFR mutated NSCLC cells.
Together, these data show that the growth of TKI resistance in EGFR
mutated NSCLC is linked to EGFR palmitoylation. Further, our data
indicate that modification of EGFR by palmitoylation influences its
cellular distribution, particularly favoring its nuclear translocation
in TKI-resistant EGFR mutated NSCLC cells.
Pharmacological inhibition of FASN by Orlistat impedes EGFR
palmitoylation, enhances its ubiquitination, and suppresses
TKI-resistant EGFR mutant NSCLC cell growth
To prove the importance of FASN in Gefitinib-resistant EGFR mutant
NSCLC cells, we evaluated the effect of its pharmacological inhibi-
tion by using the FASN inhibitor Orlistat. Cellular proliferation and
viability in Gefitinib-resistant PC-9GR and H1975 cells were
measured by exposing them to increasing drug concentrations, as
well as vehicle control (DMSO) for 72 h. The NL20 cell line was
included as control. Gefitinib treatment was compared to Orlistat
efficacy. TKI-resistant EGFR mutant NSCLC cells exhibited greater
sensitivity to Orlistat exposure at 100 lM, indicated by lower
growth rates, as compared to NL20 cells (Fig 5A). We then asked
whether the lower dependency on FASN is attributed to inactivity of
EGFR wild-type in NL20 cells. Viability assays showed that stimula-
tion of EGFR with EGF in NL20 cells did not affect its sensitivity to
Orlistat, when compared to EGF alone or vehicle (Appendix Fig
S13A). Western blot images demonstrated that EGFR activity
(Y1068), SREBP1 and FASN expressions, after Orlistat exposure,
remained similar to that of vehicle- plus EGF-treated NL20 cells
(Appendix Fig S13B). Together, these results show the efficacy of
Orlistat in affecting proliferation and viability of TKI-resistant EGFR
mutant NSCLC in cell culture systems.
Next, we examined whether there was a correlation between the
inhibitory effects of Orlistat and expression of EGFR, FASN, and
apoptotic-related proteins. Western blot data obtained in PC-9GR
and H1975 cells demonstrated that Gefitinib exposure failed to
induce Bax and Bak, and concomitantly did not repress survivin, as
predicted by their resistance to Gefitinib (Fig 5C). NL20 cells exhib-
ited a similar resistance to Gefitinib. Orlistat exposure, however, led
to the upregulation of Bax and Bak, concomitant with loss of EGFR,
FASN, and survivin expression in NSCLC cells, as compared to vehi-
cle-treated cells. Conversely, in NL20 cells, Orlistat was able to
inhibit FASN expression, however failed to induce Bax and Bak
expression, and therefore failed to reduce EGFR and survivin
expression. The importance of FASN in Gefitinib-resistant EGFR
mutant NSCLC cells was recapitulated with FASN knockdown with
siRNAs (Appendix Fig S14A and B). Further, the addition of exoge-
nous palmitate improved cell growth of FASNi-treated PC-9GR and
H1975, but not H1703 cells carrying wild-type EGFR (Appendix Fig
S15). Together, these data demonstrate that FASN inhibition
induces EGFR loss and suppresses the growth of TKI-resistant EGFR
mutant NSCLC cells, via inducing apoptosis.
To determine whether FASN was involved in EGFR palmitoyla-
tion in TKI-resistant NSCLC cells, we performed in vitro ABE assays
on Orlistat-treated PC-9GR and H1975 cells. Cells were treated with
Orlistat for 24, 48, and 72 h, and their EGFR expression was
promptly evaluated by Western blot analysis (Appendix Fig S16).
Results showed that Orlistat treatment significantly reduced EGFR
palmitoylation (Fig 5D), suggesting a functional relationship
between FASN and EGFR palmitoylation in TKI-resistant EGFR
mutant NSCLC cells. Further, since palmitoylation has been shown
to modulate protein stability by blocking its ubiquitination (Valdez-
Taubas & Pelham, 2005; Kong et al, 2013), we wondered whether a
link between palmitoylation and degradation of EGFR may be
observed in TKI-resistant NSCLC cells. Therefore, we sought to
determine the effect of Orlistat on EGFR palmitoylation in both PC-
9GR and H1975 cells. As shown by Western blot images in Fig 5E,
co-immunoprecipitation of EGFR from protein lysates showed that
Orlistat induced a dramatic increase in EGFR ubiquitination,
whereas EGFR ubiquitination after Gefitinib exposure was similar
to vehicle treatment in TKI-resistant cells. These data suggest
an inverse relationship between EGFR palmitoylation and
ubiquitination.
To evaluate the mechanism through which Orlistat causes cell
growth inhibition, we quantified apoptosis by fluorescence activated
cell-sorting (FACS) analysis and showed that Orlistat exposure
increased the percentages of apoptotic cells in PC-9GR
(22.2%  1.2% versus 3.4%  0.5%, P = 0.0001) and H1975
(30%  2.4% versus 3.1%  0.5%, P = 0.0001) as compared to
vehicle. The percentages of apoptotic cells were instead similar
between Gefitinib- and vehicle-treated cells, consistent with their
Gefitinib-resistant phenotype (Fig 5F). Importantly, the percentages
of apoptotic cells after Gefitinib or Orlistat exposure were similar to
vehicle treatment in NL20 cells. Together, our results demonstrate
that Orlistat specifically triggers apoptosis in EGFR mutant Gefitinib-
resistant NSCLC cells.
Orlistat inhibits in vivo tumorigenesis in both TKI-resistant
NSCLC EGFR mutant xenograft and EGFR-T790M-L858R
transgenic models
To determine the effectiveness of Orlistat in inhibiting tumor growth
in vivo, xenograft models of PC-9GR and H1975 cells were generated
in NSG mice. Tumor growth could be detected 5–7 days after
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inoculation, with differences in growth rates occurring after treat-
ment with Orlistat or vehicle (Fig 6A). Tumor volumes of Orlistat-
treated mice (n = 5 mice) were significantly smaller compared to
their vehicle counterparts (n = 5 mice). During the course of Orlistat
administration, there were no obvious side effects or changes in
body weight (Appendix Fig S17). Next, to determine whether Orlis-
tat affects tumor FFAs levels, we measured the FFAs in PC-9GR and
H1975 tumor xenografts by ELISA. Results showed that Orlistat
significantly reduced FFAs in PC-9GR and H1975 xenograft models
as compared to vehicle-treated groups (Fig 6B) Additionally,
Western blotting analysis demonstrated that the decreased growth
of Orlistat-treated xenograft tumors correlated with induced Bax and
Bak proteins and concomitant loss of EGFR, FASN, and survivin
expression, as compared to vehicle-exposed mice (Fig 6C). These
data demonstrate that Orlistat is effectively affecting in vivo growth
of TKI-resistant EGFR mutant NSCLC xenografts.
The in vivo efficacy of Orlistat was further examined in the trans-
genic CCSP-rTTA-EGFR L858R-T790M-driven lung adenocarcinoma
mouse model (Politi et al, 2006; Li et al, 2007). These mice develop
lung tumors when continuously exposed to doxycycline, as mutant
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Figure 5. Orlistat restricts growth in TKI-resistant EGFR mutant NSCLC cells and induces palmitoylation with concomitant enhanced ubiquitination of EGFR.
A, B Cell proliferation (n = 3, A) and viability (n = 3, B) assays on the effect of Orlistat (100 lM) on cells at indicated doses for 72 h (upper and lower panels
respectively). Significance in differences in proliferation and viability indexes, in which vehicle acted as control, was determined by t-test. Error bars denote SEM.
C Western blot analysis of EGFR, FASN, Bax, Bak, and survivin protein expression from cells exposed to either Gefitinib or Orlistat for 48 h. ACTB is selected as a
housekeeping gene. Vehicle-treated cells acted as controls.
D Western blot data showing EGFR palmitoylation in Orlistat-treated cells (48 h). Hydroxylamine (HAM), a strong reducing agent that cleaves palmitate from cysteine
residues, is necessary for biotinylation. The omission of HAM cleavage (HAM-) serves as negative control for the ABE assay.
E Western blot images showing ubiquitination status of EGFR in cells after exposure to vehicle, Gefitinib or Orlistat for 48 h.
F FACS analysis (n = 2) for Annexin V/PI staining shows percentages of early (Annexin+) and late (Annexin and PI+) apoptotic cells treated with vehicle, Gefitinib or
Orlistat for 48 h.
Source data are available online for this figure.
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EGFR becomes overexpressed in CCSP+ pulmonary epithelial cells.
Lung tumor growth was detected and carefully followed by
magnetic resonance imaging (MRI). After 5–6 weeks of induction,
baseline MRI showed tumor growth in the lungs and at such time
point, mice were randomized to vehicle (n = 6) or Orlistat (n = 7)
treatment. MRI images were taken every 2–4 days to capture the
effects of drug treatment on tumor size over a 28-day period.
Processing and quantification techniques of tumor burden were
based on manual segmentation/volume calculation of diffuse lung
tumors (Fig 7A) as described previously (Krupnick et al, 2012).
Changes in lung tumor volumes over the course of treatment were
calculated as percentage change in volume over tumor volume at
day 1 of treatment, which was set at 100% (Fig 7B). There was no
significant difference in tumor volumes between vehicle and Orlistat
groups from day 1 to day 23 of treatment. All mice were euthanized
at treatment day 28 when tumor burden of vehicle-treated mice
became too large. Interestingly, at treatment days 26 and 28, lung
tumors in the Orlistat-treated group were found to be significantly
smaller by approximately 30% than those in vehicle-treated
(Fig 7B). Tumor FFAs levels analyses showed that the tumor shrink-
age in the Orlistat-treated group correlated with significantly lower
tumor FFAs when compared to vehicle (Fig 7C). Subsequently,
Western blot images showed that FASN expression in tumors from
Orlistat-treated transgenic mice showed that tumor growth inhibi-
tion correlated with reduced FASN expression when compared to
vehicle (Fig 7D). All together, our data show the in vivo anti-tumor
activity of Orlistat as a single agent against the clinically relevant
TKI-resistant EGFR T790M/L858R mutation.
Discussion
Chemotherapy resistance remains a major problem in limiting the
efficacy of conventional and molecular-targeted cancer therapies.
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Figure 6. Orlistat reduces tumor sizes in PC-9GR and H1975 NSCLC xenograft models.
A Growth curve of xenografts from NSG mice treated with either vehicle (n = 5) or Orlistat (n = 5) at 240 mg/kg body weight (upper panels). Representative images of
xenografts from vehicle- and Orlistat-treated mice (lower panels). Significance in differences in tumor sizes, in which vehicle acted as control, was determined by
t-test. Error bars denote SEM.
B Measurement of FFAs from tumors derived from vehicle- or Orlistat-treated xenograft mice (n = 5 each group). Significance in differences in FFAs, in which vehicle
acted as control, was determined by t-test. Error bars denote SEM.
C Western blot analysis of EGFR, FASN, Bax, Bak, and survivin expression in protein extracts from representative xenograft tumors treated with vehicle- and Orlistat-
treated groups.
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This problem is particularly evident in lung cancer, in which,
despite the advances in therapeutic options such as EGFR-TKIs,
mortality rate still remains among the highest of cancer-related
deaths (Kobayashi et al, 2005). Hence, there is an unmet need to
identify novel targetable signaling pathways in NSCLC for therapeu-
tic intervention.
To this aim, our initial approach involved chronic adaptation of
EGFR del746-750 PC-9 NSCLC cells to increasing doses of Gefitinib
over a 6-month duration (Ogino et al, 2007; Rho et al, 2009). Impor-
tantly, DNA analyses from PC-9GR ruled out the link between the
development of acquired resistance to Gefitinib of PC-9GR cells and
secondary EGFR T790M mutation, which is the most common
mechanisms of acquired TKI resistance in NSCLC (Yun et al, 2008;
Sequist et al, 2011). Comparison of global gene expression profiles
between PC-9P and PC-9GR cells subsequently uncovered the asso-
ciation of upregulation of fatty acid metabolism pathway genes with
acquired Gefitinib resistance. Most importantly, top-ranked FASN is
an attractive molecule for targeted therapy for the following
reasons; first, it plays a pivotal role in de novo fatty acid synthesis
(Guo et al, 2009); second, it is found to be overexpressed in various
malignancies including those of the lung (Gansler et al, 1997;
Fiorentino et al, 2008; Horiguchi et al, 2008; Migita et al, 2009);
and finally, a clear distinction of fatty acid synthesis exists between
adult non-transformed cells and tumors, in that non-transformed
cells preferentially use circulating fatty acid (FA) for synthesis of
lipids, whereas tumors exhibit elevated de novo FA synthesis, irre-
spective of the extracellular lipid levels (Kuhajda, 2000). Although
FASN overexpression has been linked to NSCLC, its association with
acquired TKI resistance has not been reported.
A series of experiments unveiled an active regulatory network
comprising EGFR and FASN, via SREBP1, that is important for both
growth and survival of PC-9GR cells. We have demonstrated that
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Figure 7. Orlistat shows anti-tumoral activity in EGFR T790M/L858R transgenic model.
A Representative image depicting the determination of tumor burden through manual segmentation. Tumor burden is measured by first defining the lung area, and
subsequently determining the average MRI lung image intensity for tumor volume in relation to normal lung volume.
B Graph shows percentage of change in tumor volume between Orlistat- (n = 7) and vehicle-treated (n = 6) groups. Significance in differences in tumor volumes, in
which vehicle acted as control, was determined by t-test. Error bars denote SEM.
C Measurement of FFAs from tumors of vehicle- or Orlistat-treated transgenic mice (n = 5 for vehicle and n = 6 for Orlistat groups). Significance in differences in tumor
FFAs levels, in which vehicle acted as control, was determined by t-test. Error bars denote SEM.
D Western blot showing FASN expression in protein extracts from representative tumors from vehicle- and Orlistat-treated groups.
Source data are available online for this figure.
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despite the presence of Gefitinib, EGFR expression persists and is
found to be crucial in the survival of TKI-resistant cells, whereas
forced EGFR ablation by siRNAs restricted their growth. Further, the
relevance of EGFR-FASN network is uncovered in another acquired
resistant EGFR mutated NSCLC cells, HCC4006GR (EGFRdel746-
749/A750P), which was generated via the chronic adaptation
method. This observation is consistent with an earlier study suggest-
ing EGFR as a valid target in EGFR-TKI-resistant NSCLC cells
(Kobayashi et al, 2005). Further, in the presence of Gefitinib, persis-
tent EGFR expression correlates with the protein levels of FASN and
its activator, SREBP1. Abrogation of FASN and SREBP1 expression
by siRNAs-mediated EGFR knockdown demonstrated they are
downstream targets of EGFR. FFAs were noticeably elevated in the
presence of Gefitinib, which could be lessened to basal levels with
EGFR knockdown, suggesting that regulation of cellular fatty acid is
EGFR-mediated. The EGFR-FASN link, however, is absent in TKI-
sensitive EGFR mutant (PC-9P and HCC4006P) and EGFR wild-type
(H1703) NSCLC cells, indicating that the novel molecular link we
herein report is confined to Gefitinib-resistant NSCLC cells with
EGFR mutant status, and independent of EGFR T790M mutation. An
explanation for this observation is the acquisition of additional
oncogenic changes in EGFR mutant cells that may converge to
tighten the EGFR-FASN axis.
Another important observation of this study was that overex-
pression of EGFR mutant proteins prevented growth arrest in EGFR
silenced cells, by re-establishing FASN expression, and this
phenomenon was restricted to Gefitinib-resistant EGFR mutant (PC-
9GR and H1975) cells. Furthermore, in these cells, failure to prevent
growth arrest through EGFR wild-type overexpression suggests that
EGFR mutations are important genotypic determinants in the regu-
lation of FASN. In addition, overexpression of EGFR mutant or
wild-type does not prevent growth arrest in EGFR silenced Gefi-
tinib-resistant EGFR wild-type H1703 cells. A plausible explanation
for these observations is the involvement of unknown oncogenic
signaling pathways activated by EGFR mutants that arose from the
adaptation of cells from prolonged exposure to Gefitinib. The Akt
signaling pathway is known to be a downstream target of EGFR,
and EGFR activating mutations have been reported to deregulate
this pathway in cancer (Wong et al, 2010). In this study, we have
shown that active Akt pathways is a conditio sine qua non to allow
survival of Gefitinib-resistant EGFR mutant (PC-9GR and H1975)
cells. Accordingly, growth arrest is observed after EGFR knockdown
causes loss of Akt activity. Furthermore, EGFR signaling through
Akt increases the demand of EGFR mutant cells for fatty acid
synthesis, resulting in the upregulation of FASN and rapid division
of tumor cells (Guo et al, 2009; Laplante & Sabatini, 2009; Lamming
& Sabatini, 2013).
In this study, we uncover a mechanism of acquired TKI resistance
in NSCLC mediated by mutated EGFR in which we demonstrate that
EGFR is palmitoylated in PC-9GR and H1975 cells. Protein palmitoy-
lation is the most common acylation of proteins in mammalian cells,
and it involves lipid modification of cysteine residues with 16-carbon
fatty acid palmitate, which is synthesized by FASN (Kuhajda, 2000;
Fiorentino et al, 2008; Guo et al, 2009; Laplante & Sabatini, 2009;
Wong et al, 2010; Aicart-Ramos et al, 2011; Lamming & Sabatini,
2013). Our data demonstrate that FASN-mediated palmitoylation
positively regulates EGFR and is confined to TKI-resistant NSCLC
with mutated EGFR. Importantly, our results show that
palmitoylation alters the cellular distribution of EGFR in TKI-resis-
tant EGFR mutated cells. The use of palmitoylation inhibitor or
removal of cysteine residues within EGFR cytosolic tail demonstrates
that palmitoylation is crucial for the nuclear translocation of EGFR
and growth of these cells. Although nuclear EGFR expression has
been reported in various malignancies, its expression in highly
proliferating normal cells suggests that nuclear EGFR has an impor-
tant role in normal biology (Brand et al, 2011). Further, the identifi-
cation of nuclear EGFR complexes in various tumor types suggests
that downstream target genes of nuclear EGFR, as transcription
factor, are distinct and cell type specific (Brand et al, 2011).
The functional role of EGFR palmitoylation is presently unclear.
Bollu et al (2015) reported findings similar to ours that FASN-
dependent palmitoylation positively regulates EGFR and supports
cancer cell growth whereas Runkle et al (2016) showed that palmi-
toylation suppresses EGFR signaling by “pinning” the C-terminal
tail of the receptor to the plasma membrane. Further, Bollu et al
(2015) showed that palmitoylation is important for plasma
membrane localization of EGFR, while Runkle et al (2016) demon-
strated that palmitoylation inhibition promotes EGFR ubiquitination
and prevents its trafficking to the endosomes. In contrast, we
demonstrated that palmitoylation is crucial for the nuclear translo-
cation of mutated EGFR. A rationale for the differences seen in the
functional impact of palmitoylation on EGFR is that the mutational
status of EGFR may influence the functional role of palmitoylation
on EGFR, as structural differences exist between wild-type and
mutant EGFRs (Yun et al, 2007; Lowder et al, 2015). It is hence
possible that these structural differences contribute to different
binding protein partners caused by the underlying mutation within
the EGFR tyrosine kinase domain that facilitates its palmitoylation
and trafficking.
Pharmacological inhibition of FASN by Orlistat blocks EGFR
palmitoylation and affects survival of PC-9GR and H1975 cells.
Further, we show that loss of palmitoylation correlates with loss of
EGFR protein expression, possibly through ubiquitin-mediated
degradation. Orlistat, an anti-obesity drug which targets FASN via
its thioesterase domain, has shown to possess anti-proliferative
properties and induces apoptosis in tumor cells derived from vari-
ous malignancies (Pizer et al, 1996; Pemble et al, 2007; Carvalho
et al, 2008; Zecchin et al, 2011). Accordingly, treatment of PC-9GR
and H1975 cells with Orlistat restricted the proliferation and viabil-
ity of these cells with increased apoptotic cells, activation of apopto-
sis through upregulation of Bax and Bak, and concomitant loss of
EGFR, FASN, and survivin. Additionally, the growth suppression
imparted by Orlistat in HCC4006GR, H820, and H1650 cells carrying
mutated EGFR strongly suggests that FASN is a valid target in TKI-
resistant EGFR mutated NSCLC.
As a proof-of-principle follow-up to our in vitro findings, we
utilized two murine models to further validate our results in in vivo
settings. We established NSG xenografts carrying human lung cancer
TKI-resistant cells that were subdivided into Orlistat- and vehicle-
treated cohorts. According to our in vitro data, Orlistat treatment
induced significant tumor volume reduction versus vehicle-exposed
animals (Agostini et al, 2014), in mice carrying EGFR mutant PC-9GR
and H1975 xenografts, by 58 and 49%, respectively. Further, reduced
tumor size was paralleled by lower FFAs levels, as well as loss of
EGFR, FASN, and survivin expression, concomitant to upregulation of
Bax and Bak proteins in in situ tumors. Orlistat anti-tumor activity
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in vivo was further validated in transgenic mouse model expressing
the clinically relevant EGFR T790M/L858R mutation, in which at
termination of treatment, drug-exposed animals presented with
approximately 30% decrease in tumor mass (assessed by MRI) as
compared to vehicle-treated transgenic mice.
Advances in understanding tumor metabolism in recent years
have shown a complex metabolic rewiring necessary for tumor cell
adaptations in adverse conditions for survival. Our results are the
first to reveal the role of EGFR in controlling FASN signaling in
acquired TKI-resistant EGFR mutant NSCLC cells, independent of
EGFR T790M mutation. Further, our data demonstrate a functional
relationship between EGFR mutant and FASN, in which lipid modifi-
cation of EGFR by palmitate, the final product of FASN, is important
for survival of TKI-resistant cells carrying EGFR mutation, as
depicted in Fig 8. However, more research is needed to identify and
elucidate how mutant and wild-type EGFR are palmitoylated, and to
gain a better understanding on the function/s played by nuclear
EGFR in TKI-resistant EGFR mutated NSCLC.
Besides these new avenues of investigation, the important clini-
cal implication of this work is to provide supportive rationale to
blocking the fatty acid metabolic pathway in EGFR mutant NSCLC
patients, notably in non-responders and/or in those who developed
resistance to anti-EGFR therapy. Although the FDA-approved FASN
inhibitor, Orlistat, is shown to be effective in reducing tumor cells
in vivo, one main limitation is its extremely low oral bioavailability,
as Orlistat exerts its effects primarily in the gastrointestinal tract,
where it inactivates pancreatic lipase (McNeely & Benfield, 1998).
Improved formulation of Orlistat-like inhibitors of FASN could
represent a promising therapeutic modality in the treatment of lung
cancer.
Materials and Methods
Cell culture
Human lung cancer cells [EGFR mutants (PC-9, HCC4006, H1650,
H820, and H1975), EGFR wild-type (H1703) and immortalized non-
transformed lung (NL20) were purchased from the American Type
Culture Collection (ATCC). These cells tested negative for myco-
plasma (Appendix Fig S18; MycoAlert assay from Lonza LT07-218)
and were authenticated via DNA fingerprinting (Appendix Fig S19).
The mutation status of EGFR for the NSCLC cell lines is summarized
in Appendix Table S3. These cells were maintained in RPMI supple-
mented with 10% FBS (Hyclone) and penicillin/streptomycin (P/S).
All cell lines were grown at 37°C in a humidified incubator with 5%
CO2. For ubiquitin experiments, MG132 (M7449, Sigma) was added
to cells, at a final concentration of 5 lM, 24 h before harvesting to
inhibit proteasome activity. Cells were grown to 70–80% conflu-
ence, harvested with trypsin, and suspended to the cell density
required for each assay.
Reagents
Short-interfering RNAs targeting EGFR#1 (50-CAGGAACTGGA
TATTCTGAAA-30), EGFR#2 (50-AAGTGTGTAACGGAATAGGTA-30),
FASN (50 – TGGAGCGTATCTGTGAGAA-30) and AKT (50-AATCA
CACCACCTGACCAAGA-30) were purchased from Qiagen. Scram-
bled (non-targeting siRNAs, purchased from Dharmacon (D-001810-
01), will be referred to as scrambled in the main text. Anti-EGFR
(sc-03, 1:1,000), SREBP1 (sc-8984, 1:1,000), FASN (sc-20140,
1:1,000), b-actin (ACTB, sc-47778, 1:2,000), Lamin B (sc-6217,
1:1,000), and a-tubulin (sc-8035, 1:1,000) antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
total Akt (#9272, 1:1,000), phospho-Akt S473 (#9271, 1:1,000),
NaK-ATPase (#3010, 1:1,000), K48-linked specific Ubiquitin (#4289,
1:1,000), Bax (#2772, 1:1,000), Bak (#3814, 1:1,000), and survivin
(#2808, 1:1,000) antibodies were purchased from Cell Signaling.
Anti-tGFP antibody was purchased from Thermo Scientific (PA5-
22688, 1:1,000). Anti-phospho EGFR Y1068 was purchased from
Abcam (ab5644, 1:2,000). 2-bromopalmitic acid (#238422), palmi-
tate (P9767), and EGF (E9644) were purchased from Sigma. Geftinib
(S1025) and Erlotinib (S1023) were purchased from SelleckChem.
Xenical capsules (Orlistat) were purchased from Roche and prepared
according to Knowles et al (2004), for cell culture experiments.
Microarray
Total RNA prepared from parental and Gefitinib-resistant PC-9 cells
was used to probe Illumina HT-12v4 chip. Data analysis was carried
out with background correction using Genespring software and
was average normalized. Test samples were considered to be
EGFR mutant
FASN
Akt
Orlistat
SREBP1
Palmitate
Tumor cell survival
Gefitinib
Figure 8. Schematic diagram of the proposed model depicting the
functional relationship between EGFR and FASN in TKI resistance within
EGFR mutant NSCLC cells.
In TKI-resistant EGFR mutant cells, the Gefitinib-untargetable palmitoylated
EGFR positively impinges on FASN, therefore promoting tumor cell growth via
the Akt pathway. Palmitoylation is a process where a 16-carbon fatty acid
palmitate, synthesized by FASN, is covalently attached to proteins.
Pharmacological inhibition of FASN by Orlistat inhibits EGFR palmitoylation and
restricts tumor cell survival.
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differentially expressed when they crossed the threshold of detection
P-value ≤ 0.05 and differential score P value ≤ 0.05 among all the
samples. Significantly differentially expressed genes were annotated
with functional assignments to help determine which gene cate-
gories were enriched with differentially expressed genes based on
the Gene Ontology (GO) database: biological process, molecular
function, and cellular component; 1,000 differentially expressed
genes were identified at a 1% false discovery rate by SAM analysis
(Tusher et al, 2001).
Cell proliferation and viability assays
Cells were plated in 96-well plates at a density of 3,000–5,000 cells/
dish in complete medium for 24 h at 37°C in 5% CO2. Cells were
then treated with the indicated agents the following day. All samples
were assayed in quadruplicates to generate proliferation and viabil-
ity curves using 5-bromo-20-deoxyuridine (BrdU assay, #6813, Cell
Signaling) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS, G3580, Promega)
assays, respectively.
Gene knockdown
Cells were grown at 50–60% confluence and transfected with 10 or
25 nmol/l of siRNAs using Lipofectamine RNAiMax (#13778, Invit-
rogen) for 72 h. For negative control, cells were transfected with
scrambled siRNAs (non-targeting).
Mutagenesis and vector transfection
The pCMV6 GFP-tagged EGFR wild-type and mutant (delE746-750
and L858R) constructs were purchased from Origene. The T790M
mutation was introduced into the EGFR L858R construct using Quick
Change Lightning Multi Site-Directed Mutagenesis kit (#210519,
Agilent Technologies) according to the manufacturer’s instructions.
The mutagenic primer sequences for EGFR L858R are forward 50-
GCATGAGCTGCATGATGAGCTGCACGGTGG-30 and reverse 50-
CCACCGTGCAGCTCATCATGCAGCTCATGC-30. For palmitoylation
study, the mutagenic primers for are EGFR C797A forward 50-
CTCATGCCCTTCGGCGCCCTCCTGGACTATGT-30 and reverse 50-
ACATAGTCCAGGAGGGCGCCGAAGGGCATGAG-30; C1049A forward
50-CAGCCCATTTCTATCAATGGCAGCCACGGTGGAATTGTTG-30 and
reverse 50-CAACAATTCCACCGTGGCTGCCATTGATAGAAATGGG
CTG-30 and C1146A forward 50-GAATGTGCTGTTGACAGCGGTGGGC
TGGACAGTG-30 and reverse 50-CACTGTCCAGCCCACCGCTGTCA
ACAGCACATTC-30. For EGFRdel391-394, the mutagenic primers are
forward 50-CTCCTCTGGATCCACAGCTGAAAACCGTAAAGGAA-30 and
reverse 50-TCCTTTACGGTTTTCAGCTGTGGATCCAGAGGAG-30. All
constructs were confirmed by DNA sequencing. Transfection of
EGFR-GFP-tagged expression vectors into cells was performed using
Fugene HD (E2311, Promega) following the manufacturer’s instruc-
tion. Briefly, cells (50–60% confluence) were seeded in six-well
plates and allowed to attach overnight, and they were incubated
with DNA-Lipofectamine mixture comprising 1 lg DNA and 3 ll
Fugene 6 reagent diluted in OPTI-MEM (Invitrogen) for 48–72 h.
Cells transfected with pCMV6-AC-GFP empty vectors acted as
controls. Transfection efficiency was determined visually and by
protein expression.
Quantitative PCR
5 lg of total RNA was reverse-transcribed in a volume of 50 ll
using 18-mer oligo-dTs and MMLV reverse transcriptase (Invitro-
gen). 1 ll of 10-fold diluted reverse transcription reactions was then
subjected to PCR in 20 ll reactions with SYBR Select Mastermix
(Life Technologies) and using the primer sequences adapted from
PrimerBank (Wang et al, 2012) using ABI Prism system (Applied
Biosystem). ACTB mRNA levels were measured by quantitative RT–
PCR in replicate samples as housekeeping gene for normalization of
different mRNA expression and the data are presented as “mRNA
Expression”. Primer sequences are listed in Appendix Table S4.
Immunoblot analysis
Post-treatment cultured cells were collected at specific times and
solubilized in Cellytic M buffer (C2978, Sigma) with protease and
phosphatase (Roche) inhibitor cocktail. Proteins were separated by
SDS–PAGE, transferred to PVDF membranes (Thermo), and detected
using Western Bright ECL (Advansta, CA).
Immunoprecipitation
Cells were harvested followed by sonication in lysis buffer [150 mM
NaCl, 0.5% NP-40, 1 mM EDTA, 20 mM Tris (pH 7.4), commercial
protease and phosphatase inhibitor cocktail] for 10 s. The lysates
were cleared by centrifugation and subsequently incubated with
relevant or control antibodies for 2.5 h with rotation at 4°C. Protein
G beads were then added followed by 1.5 h rotation at 4°C.
Immunoprecipitates were then resolved on SDS–PAGE gels.
Cellular fractionation
Cells were fractionated using the nuclear fractionation kit (#40010,
Active Motif) into nuclear, cytosolic, and membrane fractions.
Briefly, cells were trypsinized and rinsed twice with PBS containing
phosphatase inhibitors. Cell pellets were obtained after centrifuga-
tion at 300 g for 5 min and suspended in 1× hypotonic buffer
containing phosphatase inhibitors. Cells were incubated on ice for
15 min to allow cells to swell, followed by addition of detergent
(supplied by manufacturer), and cells were vortexed vigorously for
10 s. This was followed by immediate centrifugation for 30 s at
14,000 g. The supernatant (cytosolic fraction) was transferred to a
new eppendorf tube, and pellet (nuclear and membrane fractions)
was resuspended in complete lysis buffer. The resuspended pellet
was further incubated for 30 min on ice on a rocking platform set at
150 rpm. The suspension was vortexed for 30 s and centrifuged at
14,000 g for 10 min at 4°C. Supernatant (nuclear fraction) was
transferred to a new tube, and the pellet (membrane fraction) was
resuspended in SDS–PAGE sample buffer.
In vitro acyl-biotin exchange (ABE) assay
The ABE assay is adapted from Wan and colleagues, with modifi-
cations (Wan et al, 2007). Cells were lysed in lysis buffer (LB
pH7.4) containing 50 mM Tris–HCl pH7.4, 150 mM NaCl, 1% NP-
40, 1 mM EDTA, and protease inhibitors. For this protocol, all
centrifugation steps are carried out at 850 g for 5 min. EGFR was
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first immunoprecipitated from 100 lg of protein using 5 lg of anti-
EGFR antibody, and complexes of EGFR and anti-EGFR antibody
were bound to Protein G Sepharose 4 beads (#17-0618-02, GE
Healthcare). 50 mM of N-ethylmaleimide (NEM, E3876, Sigma) in
LB pH7.4 was then added to the immunoprecipitated EGFR and
incubated 3 h at 4°C with gentle rotation to block free thiols of
cysteine residues. After three washes with LB pH7.4, EGFR was
treated with and without (mock as control) 1 M of hydroxylamine
(HAM, #379921, Sigma) in LB pH7.4 for 2 h at room temperature
with gentle rotation. EGFR was then rinsed three times with LB
pH6.2 followed by treatment with 5 lM of BMCC-Biotin (#21900,
Thermo Fischer Scientific) in LB pH6.2 for 2 h at room temperature
with gentle rotation. This was followed by three rinses with LB
pH7.4 to remove excess biotin, and EGFR was then eluted with
reducing sample buffer. Samples were analyzed by SDS–PAGE gels.
In vitro palmitoylation of cell-free synthesized EGFR
Cell-free tGFP-tagged EGFR vectors, containing wild-type, del746-750
or L858R/T790M, were generated using the 1-Step Human Coupled
IVT kit (8882, Thermo Scientific) according to manufacturer’s proto-
col. For fresh cellular extract preparation from PC-9GR, H1975, and
H1703, cells were grown on 10-cm dish and are lysed in 500 ll of
hypotonic buffer containing 10 mM Tris–HCl pH7.4, 10 mM NaCl,
3 mM MgCl2, 0.1% NP-40. Lysates were passed through 27G needle
ten times, and cell debris was removed by centrifugation at 500 g for
5 min at 4°C. Cleared lysates were kept on ice. For in vitro palmitoy-
lation, synthesized tGFP-tagged EGFR was incubated with fresh cellu-
lar extracts in 2× NT buffer (50 mM Tris–HCl pH7.4 and 300 mM
NaCl) for 1 h at 37°C. Half-portion of all reactions were then
subjected to ABE assay, and followed by Western blotting. Anti-tGFP
antibodies were then used to probe for EGFR.
Free fatty acid measurement
Total lipids were extracted according to manufacturer guidelines (Free
Fatty Acid Quantification Kit, ab65341, Abcam). Briefly, fatty acids
were converted to their CoA derivatives and subsequently oxidized
with concomitant generation of color. C-8 (octanoate) and longer fatty
acids were quantified by colorimetric (spectrophotometry at = 570 nm)
with detection limit 2 lM free fatty acid in samples. Relative free fatty
acids were quantified based on the cell number (1 × 106) and tumor
weight (5 mg) for cell lines and tumors, respectively.
Cell cycle
Cells (both free and attached) were harvested and incubated with
propidium iodide solution in PBS at final concentration of 50 ng/ml
for 5 min in the dark. Cell cycle analyses were carried out with a
FACScan flow cytometer (BD Biosciences). Cell cycle distributions
and sub-G1 fractions were calculated using CellQuest software (BD
Biosciences, San Jose, CA).
Flow cytometric analyses
Flow cytometric analyses were carried out on single-cell suspen-
sions and were analyzed by FACScan using CellQuest software (BD
Biosciences, San Jose, CA). Apoptosis assay was performed with an
Annexin V-FITC Apoptosis Detection Kit #556547 (BD Biosciences,
San Jose, CA). Briefly, harvested cells were suspended in 100 ll of
the binding buffer followed by additions of 5 ll Annexin V-FITC
and 5 ll propidium iodide (PI, 20 mg/ml) and samples were incu-
bated for 15 min at room temperature in dark. Finally, binding
buffer (400 ll) was added to each reaction tube and cells were
analyzed by flow cytometry.
Xenograft model
Animal experimental protocols were approved by the NUS Institu-
tional Animal Care and Use Committee (Protocol R14-579). Male
NOD scid gamma (NSG) mice were obtained from the Xenograft
Cancer Model Facility, Cancer Science Institute Singapore, and main-
tained in the National University of Singapore Animal Facility
throughout this study. PC-9GR and H1975 NSCLC cells were used for
injection. There were two groups for each cell line—vehicle- and
Orlistat-treated. Mouse numbers were determined using the formula:
n = log/log p, where n = number of animals that need to be tested,
0.05 = the probability of committing a type II error/p = the propor-
tion of the animals in the colony without tumor growth (Dell et al,
2002). For our study, we use = 0.05, as we wish to have a 95%
chance of detecting the event of tumor formation and we expect the
incidence of tumor formation to be 50% in our study. Hence,
P = 0.50. n = log/log p = log 0.05/log 0.50 = 4.33. Mice were
randomized, in which even numbered mice were allocated to vehicle
group whereas odd numbered mice were allocated to Orlistat group
(n = 5 for each group). Experimenters were blinded to the treatment
groups to avoid bias. Cells were suspended at 3 × 106 in 200 ll of 1
part PBS: 1 part Matrigel solution (#356234, Corning, MA) and
implanted into the right flank of 6- to 8-week-old NSG mice using a
syringe with a 27 gauge disposable needle (BD Biosciences). Mice
were previously anesthetized with isoflurane by inhalation at 3–4%
(Baxter, IL). When tumors reached approximately 4 mm in diame-
ter, mice were treated with either Orlistat (240 mg/kg) or vehicle by
intraperitoneal injections for five consecutive days per week. For
mice injection, Orlistat was prepared according to Kridel et al
(2004), with minor modifications. Tumors were measured with
caliper every 3 days and their volumes calculated using the formula
volume 0.5 × length × width2. Mice were then sacrificed by CO2
inhalation when tumor reached a diameter of 15 mm in vehicle
group or presented with ulceration at tumor site. Tumors were
harvested and snap frozen in liquid nitrogen and stored at 80°C.
CCSP-rtTA-EGFRT790M/L858R transgenic model
All animals were housed in specific pathogen-free housing with
abundant food and water under guidelines approved by the BIDMC
Institutional Animal Care and Use Committee and Animal Research
Facility. CCSP-rtTA tetracycline-dependent activator mice (Tichelaar
et al, 2000) and tet-regulatable EGFRL858R+T790M mice (Li et al,
2007) have been previously described, were a kind gift from Dr
Kwok-Kin Wong, and were maintained on a C57BL/6 genetic back-
ground. Calculations to determine mouse numbers are similar to the
formula used for Xenograft model. However, we expect the inci-
dence of tumor formation to be 40% in the transgenic model.
Hence, P = 0.60. n = log/log p = log 0.05/log 0.60 = 5.86. To
induce EGFR expression, doxycycline was administered by feeding
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both male and female mice with doxycycline-impregnated food
pellets (625 ppm; Harlan-Teklad). Eight- to ten-week-old mice were
fed with doxycycline to induce lung tumors. Mice were then imaged
by magnetic resonance (MRI) to detect baseline tumors and subse-
quently recruited into treatment groups. Utilizing randomization
process similar to that for Xenograft model, six (two males and four
females) and seven (three males and four females) mice were allo-
cated to vehicle and Orlistat treatment groups, respectively. Experi-
menters were blinded to the treatment groups to avoid bias. The
preparation and administration of Orlistat was as described earlier
in Xenograft model. MRI images of mouse lungs were captured with
a Bruker Biospec 94/20 9.4 Tesla scanner, and the primary imaging
sequence used was RARE (Rapid Acquisition with Refocused
Echoes), with TR/TE = 1,200 ms/17.5 ms.
Statistical analysis
Results from cell proliferation and viability assays, Q-PCR and FFAs
quantification were from at least two independent experiments and
each performed in quadruplicates, are shown as means  SEM. All
statistical analyses, including in vivo studies, were performed using
t-test and P < 0.05 was considered statistically significant.
Data availability
The Microarray Gene Expression data have been deposited to the
Gene Expression Omnibus (GEO) repository (GEO Accession
Number: GSE83666).
Expanded View for this article is available online.
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